Payment overview · 2025
General Payments
$1,334.92
69 reported records · 16 companies
Healthcare provider profile · identity verified
Edwin Lee Linder, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BATESVILLE, MS · NPI 1679652408
Verified facts
What the public records show
CMS Open Payments records show Edwin Lee Linder, M.D. received $1,334.92 in general payments during 2025 across 69 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 538 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $233.75 | 17.5% | 10 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $202.42 | 15.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.64 | 14.4% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $139.39 | 10.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.18 | 9.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.85 | 7.8% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $100.96 | 7.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.87 | 4.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.81 | 3.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.52 | 2.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.74 | 1.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.87 | 1.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.37 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.93 | 1.3% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $16.35 | 1.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.27 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,334.92 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $202.42 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $157.32 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.18 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $114.80 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.58 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $102.99 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.15 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.98 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.07 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.10 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.52 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $16.35 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 127 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 133 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
133 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
127 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
278 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
131 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
538 | 105 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1524 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 1405 | 352 |
| Furosemide | Furosemide | 1028 | 227 |
| Pantoprazole Sodium | Pantoprazole Sodium | 987 | 246 |
| Potassium Chloride | Potassium Chloride | 984 | 238 |
| Levothyroxine Sodium | Levothyroxine Sodium | 974 | 229 |
| Omeprazole | Omeprazole | 827 | 203 |
| Carvedilol | Carvedilol | 786 | 191 |
| Tamsulosin Hcl | Tamsulosin Hcl | 767 | 168 |
| Metformin Hcl | Metformin Hcl | 711 | 202 |
| Losartan Potassium | Losartan Potassium | 689 | 204 |
| Gabapentin | Gabapentin | 682 | 166 |
| Eliquis | Apixaban | 538 | 105 |
| Clopidogrel | Clopidogrel Bisulfate | 531 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 475 | 141 |
| Meloxicam | Meloxicam | 472 | 157 |
| Donepezil Hcl | Donepezil Hcl | 467 | 87 |
| Trazodone Hcl | Trazodone Hcl | 445 | 86 |
| Sertraline Hcl | Sertraline Hcl | 441 | 82 |
| Famotidine | Famotidine | 437 | 118 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 436 | 138 |
| Montelukast Sodium | Montelukast Sodium | 407 | 105 |
| Lisinopril | Lisinopril | 403 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 122 |
| Buspirone Hcl | Buspirone Hcl | 348 | 71 |
| Allopurinol | Allopurinol | 336 | 69 |
| Glimepiride | Glimepiride | 326 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 322 | 93 |
| Quetiapine Fumarate | Quetiapine Fumarate | 316 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 73 |
| Simvastatin | Simvastatin | 295 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 287 | 71 |
| Jardiance | Empagliflozin | 278 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 275 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 266 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 265 | 117 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 100 |
| Duloxetine Hcl | Duloxetine Hcl | 249 | 64 |
| Divalproex Sodium | Divalproex Sodium | 246 | 31 |
| Memantine Hcl | Memantine Hcl | 222 | 31 |
| Mirtazapine | Mirtazapine | 222 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 55 |
| Lovastatin | Lovastatin | 205 | 50 |
| Amoxicillin | Amoxicillin | 201 | 168 |
| Methocarbamol | Methocarbamol | 194 | 95 |
| Tizanidine Hcl | Tizanidine Hcl | 188 | 42 |
| Lorazepam | Lorazepam | 186 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 184 | 53 |
| Spironolactone | Spironolactone | 181 | 52 |
| Levetiracetam | Levetiracetam | 180 | 35 |
| Azithromycin | Azithromycin | 179 | 158 |
| Amiodarone Hcl | Amiodarone Hcl | 177 | 40 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 167 | 57 |
| Tramadol Hcl | Tramadol Hcl | 167 | 57 |
| Xarelto | Rivaroxaban | 164 | 28 |
| Baclofen | Baclofen | 156 | 30 |
| Atenolol | Atenolol | 154 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 30 |
| Warfarin Sodium | Warfarin Sodium | 145 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 143 | 43 |
| Linzess | Linaclotide | 133 | 33 |
| Trulicity | Dulaglutide | 131 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 129 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 129 | 30 |
| Finasteride | Finasteride | 128 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 128 | 66 |
| Clonazepam | Clonazepam | 127 | 28 |
| Farxiga | Dapagliflozin Propanediol | 127 | 35 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 124 | 103 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 36 |
| Tradjenta | Linagliptin | 123 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 123 | 30 |
| Bumetanide | Bumetanide | 121 | 30 |
| Meclizine Hcl | Meclizine Hcl | 117 | 55 |
| Prednisone | Prednisone | 115 | 68 |
| Entresto | Sacubitril/Valsartan | 113 | 20 |
| Methylprednisolone | Methylprednisolone | 109 | 100 |
| Mupirocin | Mupirocin | 107 | 73 |
| Sucralfate | Sucralfate | 107 | 15 |
| Ezetimibe | Ezetimibe | 105 | 30 |
| Ozempic | Semaglutide | 104 | 26 |
| Bupropion Xl | Bupropion Hcl | 103 | 23 |
| Colchicine | Colchicine | 103 | 45 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 103 | 85 |
| Nebivolol Hcl | Nebivolol Hcl | 101 | 31 |
| Clonidine Hcl | Clonidine Hcl | 97 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 65 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 32 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 95 | 63 |
| Lamotrigine | Lamotrigine | 86 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 84 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 18 |
| Januvia | Sitagliptin Phosphate | 81 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 58 |
| Olanzapine | Olanzapine | 80 | 14 |
| Myrbetriq | Mirabegron | 77 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 75 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 16 |
| Alprazolam | Alprazolam | 72 | 22 |
| Fluconazole | Fluconazole | 71 | 47 |
| Metformin Hcl Er | Metformin Hcl | 70 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 14 |
| Risperidone | Risperidone | 68 | 15 |
| Valsartan | Valsartan | 68 | 14 |
| Glipizide | Glipizide | 66 | 19 |
| Naproxen | Naproxen | 66 | 49 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 22 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 64 | suppressed |
| Celecoxib | Celecoxib | 64 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Vascepa | Icosapent Ethyl | 63 | suppressed |
| Fenofibrate | Fenofibrate | 59 | 13 |
| Nystatin | Nystatin | 58 | 32 |
| Latanoprost | Latanoprost | 57 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Cephalexin | Cephalexin | 56 | 46 |
| Cefdinir | Cefdinir | 54 | 53 |
| Digoxin | Digoxin | 54 | 12 |
| Enalapril Maleate | Enalapril Maleate | 54 | 14 |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 53 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | suppressed |
| Lactulose | Lactulose | 52 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 51 | 17 |
| Levofloxacin | Levofloxacin | 49 | 36 |
| Midodrine Hcl | Midodrine Hcl | 48 | 18 |
| Torsemide | Torsemide | 47 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 46 | 46 |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 36 |
| Ondansetron Odt | Ondansetron | 45 | 27 |
| Clonidine | Clonidine | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 11 |
| Aripiprazole | Aripiprazole | 43 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | 12 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 41 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 12 |
| Megestrol Acetate | Megestrol Acetate | 40 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 21 |
| Ranolazine Er | Ranolazine | 38 | 12 |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 35 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Brilinta | Ticagrelor | 34 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 34 | 23 |
| Dapagliflozin | Dapagliflozin Propanediol | 33 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 12 |
| Topiramate | Topiramate | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 16 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Lacosamide | Lacosamide | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 19 |
| Dutasteride | Dutasteride | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 16 |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Letrozole | Letrozole | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 21 | suppressed |
| Paliperidone Er | Paliperidone | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 19 | 14 |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nexium | Esomeprazole Magnesium | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | 11 |
| Kevzara | Sarilumab | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,334.92 · 69 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, COMIRNATY, CREON, FARXIGA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REXULTI, Rybelsus, SMARTVEST, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, YUPELRI, ZEPBOUND, ZORYVE, Zunveyl | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error